Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma
Annals of Hematology · 28.10.2026 · 105 (11)
DOI: 10.1007/s00277-026-07277-6 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 28.10.2026. Verfasst von Ihab Karim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Carreras Leukämie Centrum, Philipps-Universität Marburg, University Hospital Giessen and Marburg, Marburg, Ger…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Histiocytic Sarcoma, Mutation, Protein Kinase Inhibitors. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Philipps-Universität Marburg.
Abstract (Originalsprache)
Histiocytic sarcoma is a rare and aggressive malignancy with poor outcomes under conventional chemotherapy. Activating MAPK pathway alterations, including BRAF V600E mutations, provide a rationale for targeted therapy; however, the durability of responses and the role of post-transplant maintenance remain unclear. We report a patient with refractory BRAF V600E -mutant histiocytic sarcoma who achieved complete remission following BRAF/MEK inhibition and subsequently underwent allogeneic stem cell transplantation. Post-transplant maintenance therapy with dabrafenib and trametinib was initiated early after engraftment. The patient achieved sustained complete remission with no radiological or molecular evidence of disease during follow-up exceeding one year. Circulating tumor DNA analysis remained negative for previously detected mutations. This case suggests that an integrated strategy combining targeted therapy, allogeneic transplantation, and post-transplant maintenance may enable durable disease control in high-risk BRAF -mutant histiocytic sarcoma and warrants further evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Carreras Leukämie Centrum, Philipps-Universität Marburg, University Hospital Giessen and Marburg, Marburg, Germany. ihab.karim@uni-marburg.de.
- Department of Hematology and Oncology, University Hospital Giessen and Marburg, Giessen, Germany.
- Institute of Pathology, University Hospital Giessen and Marburg, Giessen, Germany.
- Department of Hematology and Oncology, Carreras Leukämie Centrum, Philipps-Universität Marburg, University Hospital Giessen and Marburg, Marburg, Germany.
Förderung
- Philipps-Universität Marburg
Zitieren
APA
Karim, I., Arnold, T., Bräuninger, A., Dohse, M., Schell, F., Samra, M. A., Tarawneh, T., Burchert, A., Gattenlöhner, S., & Sohlbach, K. (2026). Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07277-6
Vancouver
Karim I, Arnold T, Bräuninger A, Dohse M, Schell F, Samra MA, et al. Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07277-6
BibTeX
@article{Karim2026,
author = {Karim, Ihab and Arnold, Tobias and Bräuninger, Andreas and Dohse, Marius and Schell, Felix and Samra, Maisun Abu and Tarawneh, Thomas and Burchert, Andreas and Gattenlöhner, Stefan and Sohlbach, Kristina},
title = {Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07277-6}
}
EUVIMED